Buy Lazolvan solution for internal use and for inhalation 7.5 mg/ml 100 ml in pharmacies
Brief description Lazolvan is a secretomotor, secretolytic, expectorant.
Pharmacological action Mucolytic and expectorant drug. Studies have shown that ambroxol, the active ingredient in Lazolvan®, increases secretion in the respiratory tract. Enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased mucus flow and transport (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and relieves cough. In patients with COPD, long-term therapy with Lazolvan® (for at least 2 months) led to a significant reduction in the number of exacerbations. There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy.
Indications Acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum and impaired mucociliary clearance: - acute and chronic bronchitis; - pneumonia; - COPD; - bronchial asthma with difficulty in sputum discharge; - bronchiectasis.
Directions for use and dosage: Oral administration (1 ml = 25 drops). Drops can be diluted in water, tea, juice or milk. The solution can be used regardless of meals. Adults and children over 12 years old - 4 ml (100 drops) 3 times a day; children aged 6 to 12 years - 2 ml (50 drops) 2-3 times a day; children aged 2 to 6 years - 1 ml (25 drops) 3 times a day; children under 2 years of age - 1 ml (25 drops) 2 times a day. Inhalations Adults and children over 6 years old - 1-2 inhalations of 2-3 ml of solution/day. Children under 6 years of age: 1-2 inhalations of 2 ml of solution/day. Lazolvan® solution for inhalation can be used using any modern equipment for inhalation (except steam inhalers). To achieve optimal hydration during inhalation, the drug is mixed with 0.9% sodium chloride solution in a 1:1 ratio. Since during inhalation therapy a deep breath can provoke a cough, inhalations should be carried out in normal breathing mode. Before inhalation, it is usually recommended to warm the inhalation solution to body temperature. Patients with bronchial asthma are recommended to carry out inhalation after taking bronchodilators to avoid nonspecific irritation of the respiratory tract and their spasm. If symptoms of the disease persist within 4-5 days from the start of using the drug, it is recommended to consult a doctor.
Side effects From the digestive system: often (1-10%) - dysgeusia (impaired sense of taste), nausea, decreased sensitivity in the oral cavity or pharynx; infrequently (0.1-1%) - dyspepsia, vomiting, diarrhea, abdominal pain, dry mouth; rarely (0.01-0.1%) - dry throat. From the skin and subcutaneous tissues: rarely (0.01-0.1%) - rash, itching*. Allergic reactions: rarely (0.01-0.1%) - urticaria; anaphylactic reactions (including anaphylactic shock)*, angioedema*, hypersensitivity*. * - these adverse reactions were observed with widespread use of the drug; with a 95% probability, the frequency of these adverse reactions is uncommon (0.1%-1%), but possibly lower; the exact frequency is difficult to estimate, because they were not noted in clinical studies.
Contraindications - first trimester of pregnancy; - lactation period (breastfeeding); - hypersensitivity to ambroxol or other components of the drug. Caution should be used in the second and third trimesters of pregnancy, in patients with renal and/or liver failure. Overdose Specific symptoms of overdose in humans have not been described. There have been reports of accidental overdose and/or medical error resulting in symptoms of known side effects of Lazolvan®: nausea, dyspepsia, vomiting, diarrhea, abdominal pain. Treatment: provocation of vomiting, gastric lavage in the first 1-2 hours after taking the drug, symptomatic therapy.
Special instructions Should not be used in combination with antitussives that impede the removal of sputum. The solution contains the preservative benzalkonium chloride, which, when inhaled, may cause bronchospasm in sensitive patients with increased respiratory tract reactivity. Lazolvan® solution for oral administration and inhalation is not recommended to be mixed with cromoglycic acid and alkaline solutions. An increase in the pH value of the solution above 6.3 may cause precipitation of ambroxol hydrochloride or the appearance of opalescence. Patients on a low-sodium diet should take into account that Lazolvan® solution for oral administration and inhalation contains 42.8 mg of sodium in the recommended daily dose (12 ml) for adults and children over 12 years of age. There are isolated reports of severe skin lesions (Stevens-Johnson syndrome and toxic epidermal necrolysis) that coincided with the use of expectorants such as ambroxol hydrochloride. In most cases, they are explained by the severity of the underlying disease and/or concomitant therapy. Patients with Stevens-Johnson syndrome or toxic epidermal necrolysis may present with fever, body aches, rhinitis, cough, and sore throat in the early phase. With symptomatic treatment, it is possible to erroneously prescribe anti-cold medications. If new lesions of the skin and mucous membranes develop, the patient should stop treatment with ambroxol and immediately seek medical help. If renal function is impaired, Lazolvan® should be used only on the recommendation of a doctor. Effect on the ability to drive vehicles and operate machinery. There were no cases of the drug influencing the ability to drive vehicles or operate machinery. Studies on the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions have not been conducted.
Interaction with other drugs No clinically significant, undesirable interactions with other drugs have been reported. Ambroxol increases the penetration of amoxicillin, cefuroxime, and erythromycin into the bronchial secretions.
Storage conditions The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 25°C. Shelf life: 5 years.
Lazolvan children's cough syrup with sputum 15 mg/5ml 100ml
A country
France
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Ambroxol
Compound
Active substance: ambroxol hydrochloride.
pharmachologic effect
Studies have shown that ambroxol, the active ingredient in the drug, increases secretion in the respiratory tract. It enhances the production of pulmonary surfactant and stimulates cipiary activity. These effects lead to increased mucus flow and transport (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and relieves cough. Pharmacokinetics: Ambroxol is characterized by rapid and almost complete absorption with a linear dose dependence in the therapeutic concentration range. Maximum plasma levels after oral administration are achieved within 1-2.5 hours. The distribution volume is 552 l. In the therapeutic concentration range, binding to plasma proteins is approximately 90%. The transition of ambroxol from the blood to tissues when administered orally occurs quickly. The highest concentrations of the active component of the drug are observed in the lungs. Approximately 30% of the administered oral dose undergoes first pass through the liver. Studies in human liver microsomes have shown that CYP3A4 is the predominant isoform responsible for the metabolism of ambroxol to dibromoantranilic acid. The remainder of ambroxol is metabolized in the liver, mainly by glucuronidation and by partial degradation to dibromoantranilic acid (approximately 10% of the administered dose), as well as a small number of additional metabolites. The terminal half-life of ambroxol is 10 hours. The total clearance is within 660 ml/min, renal clearance accounts for approximately 8% of the total clearance. No clinically significant effect of age and gender on the pharmacokinetics of ambroxol was found. therefore, there is no basis for selecting the dosage based on these characteristics.
Indications for use
Acute and chronic diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty in sputum discharge, bronchiectasis.
Mode of application
Orally. The drug is prescribed for adults and children over 12 years old: 10 ml 3 times a day; children from 6 to 12 years old: 5 ml 2-3 times a day; children from 2 to 6 years old: 2.5 ml 3 times a day ;children under 2 years of age: 2.5 ml 2 times a day. The drug can be used regardless of meals. If symptoms of the disease persist within 4-5 days from the start of treatment, it is recommended to consult a doctor.
Interaction
No clinically significant, undesirable interactions with other drugs have been reported. Increases the penetration of amoxicillin and cefuroxime into the bronchial secretions. erythromycin.
Side effect
Gastrointestinal disorders. Often – nausea; uncommon - heartburn, dyspepsia, vomiting, diarrhea, abdominal pain, dry mouth; rarely - dry throat. Immune system disorders, damage to the skin and subcutaneous tissues. Rarely - rash, urticaria; anaphylactic reactions (including anaphylactic shock), angioedema, itching, hypersensitivity. Disorders of the nervous system. Often - dysgeusia (impaired taste).
Contraindications
Hypersensitivity to ambroxop or other components of the drug, pregnancy (first trimester), lactation period.
Overdose
Specific symptoms of overdose in humans have not been described. There are reports of accidental overdose and/or medical error, as a result of which symptoms of known side effects of the drug Lazolvan were observed: nausea, dyspepsia, diarrhea, vomiting, abdominal pain. In this case, there may be a need for symptomatic therapy Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug; symptomatic therapy.
special instructions
The syrup contains 10.5 g of sorbitol based on the maximum recommended daily dose (30 ml). Patients with rare hereditary fructose intolerance should not take this drug. Use the drug with caution during pregnancy (II - III trimester), with renal and/or liver failure. Use during pregnancy and breastfeeding. Ambroxol penetrates the placental barrier. Preclinical studies have not revealed direct or indirect adverse effects on pregnancy, embryonic, fetal, postnatal development and childbirth. Extensive clinical experience with the use of ambroxol after 28 weeks of pregnancy has not found evidence of a negative effect of the drug on the fetus. However, normal precautions must be taken when using the medicine during pregnancy. It is especially not recommended to take the drug in the first trimester of pregnancy. Ambroxol can be excreted in human milk. Despite the fact that no undesirable effects were observed in breast-fed children, it is not recommended to use the drug during lactation. Preclinical studies of ambroxol have not revealed a negative effect on fertility. It should not be combined with antitussives that impede the removal of sputum. Included in the syrup sorbitol may have a mild laxative effect. In patients with severe skin lesions - Stevens-Johnson syndrome or toxic epidermal necrolysis - fever, body pain, rhinitis, cough and sore throat may appear in the early phase. During symptomatic treatment, it is possible to erroneously prescribe mucolytic agents such as ambroxol hydrochloride. There are isolated reports of the detection of Stevens-Johnson syndrome and toxic epidermal necrolysis. coinciding with the prescription of the drug: however, there is no cause-and-effect relationship with taking the drug. If the above syndromes develop, it is recommended to stop treatment and immediately seek medical help. If renal function is impaired, the drug should be used only on the recommendation of a doctor. Effect of the drug on the ability to drive vehicles and machinery. There have been no cases of the drug influencing the ability to drive vehicles and machinery. Studies on the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions have not been conducted.
